• 1
    Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM & Binder LI (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 83, 49134917.
  • 2
    Kosik KS, Joachim CL & Selkoe DJ (1986) Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci USA 83, 40444048.
  • 3
    Nukina N & Ihara Y (1986) One of the antigenic determinants of paired helical filaments is related to tau protein. J Biochem (Tokyo) 99, 15411544.
  • 4
    Lu Q & Wood JG (1993) Functional studies of Alzheimer's disease tau protein. J Neurosci 13, 508515.
  • 5
    Khatoon S, Grundke-Iqbal I & Iqbal K (1992) Brain levels of microtubule-associated protein tau are elevated in Alzheimer's disease: a radioimmuno-slot-blot assay for nanograms of the protein. J Neurochem 59, 750753.
  • 6
    An WL, Cowburn RF, Li L, Braak H, Alafuzoff I, Iqbal K, Iqbal IG, Winblad B & Pei JJ (2003) Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am J Pathol 163, 591607.
  • 7
    Pei JJ, Khatoon S, An WL, Nordlinder M, Tanaka T, Braak H, Tsujio I, Takeda M, Alafuzoff I, Winblad B, et al. (2003) Role of protein kinase B in Alzheimer's neurofibrillary pathology. Acta Neuropathol (Berlin) 105, 381392.
  • 8
    Mah VH, Eskin TA, Kazee AM, Lapham L & Higgins GA (1992) In situ hybridization of calcium/calmodulin dependent protein kinase II and tau mRNAs; species differences and relative preservation in Alzheimer's disease. Mol Brain Res 12, 8594.
  • 9
    Boutajangout A, Boom A, Leroy K & Brion JP (2004) Expression of tau mRNA and soluble tau isoforms in affected and non-affected brain areas in Alzheimer's disease. FEBS Lett 576, 183189.
  • 10
    Li X, An WL, Alafuzoff I, Soininen H, Winblad B & Pei JJ (2004) Phosphorylated eukaryotic translation factor 4E is elevated in Alzheimer brain. NeuroReport 15, 22372240.
  • 11
    Braak H & Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berlin) 82, 239259.
  • 12
    Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G & Berg L (1991) The consortium to establish a registry for Alzheimer's disease (CERAD), part II. Standardisation of the neuropathological assessment of Alzheimer's disease. Neurology 41, 476486.
  • 13
    Peterson RT, Beal PA, Comb MJ & Schreiber SL (2000) FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. J Biol Chem 275, 74167423.
  • 14
    Pei JJ, Tanaka T, Tung YC, Braak E, Iqbal K & Grundke-Iqbal I (1997) Distribution, levels and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J Neuropathol ExP Neurol 56, 7078.
  • 15
    Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B & Cowburn RF (1999) Distribution of active glycogen synthase kinase 3β (GSK-3β) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol ExP Neurol 58, 10101019.
  • 16
    Pei JJ, Braak E, Braak H, Grundke-Iqbal I, Iqbal K, Winblad B & Cowburn RF (2001) Localization of active forms of C-jun (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neufibrillary degeneration. J Alzheimer Dis 3, 4148.
  • 17
    Pei JJ, Braak H, An WL, Winblad B, Cowburn RF, Iqbal K & Grundke-Iqbal I (2002) Up-regulation of mitogen-actived protein kinase ERK1/2 and MEK 1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer's disease. Mol Brain Res 109, 4555.
  • 18
    Griffin RJ, Moloney A, Kelliher M, Johnston JA, Ravid R, Dockery P, O'connor R & O'neill C (2005) Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J Neurochem 93, 105117.
  • 19
    Gingras AC, Raught B & Sonenberg N (2001) Regulation of translation initiation by FRAP/mTOR. Genes Dev 15, 807826.
  • 20
    Herbert TP, Tee AR & Proud CG (2002) The extracellular signal-regulated kinase pathway regulates the phosphorylation of 4E–BP1 at multiple sites. J Biol Chem 277, 1159111596.
  • 21
    Brunn GJ, Hudson CC, Sekulic A, Williams JM, Hosoi H, Houghton PJ, Lawrence JC Jr & Abraham RT (1997) Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 277, 99101.
  • 22
    Hara K, Yonezawa K, Kozlowski MT, Sugimoto T, Andrabi K, Weng QP, Kasuga M, Nishimoto I & Avruch J (1997) Regulation of eIF-4E BP1 phosphorylation by mTOR. J Biol Chem 272, 2645726463.
  • 23
    von Manteuffel SR, Dennis PB, Pullen N, Gingras AC, Sonenberg N & Thomas G (1997) The insulin-induced signalling pathway leading to S6 and initiation factor 4E binding protein 1 phosphorylation bifurcates at a rapamycin sensitive point immediately upstream of p70s6k. Mol Cell Biol 17, 54265436.
  • 24
    Gingras AC, Kennedy SG, O'Leary MA, Sonenberg N & Hay N (1998) 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt (PKB) signaling pathway. Genes Dev 12, 502513.
  • 25
    An WL, Bjorkdahl C, Liu R, Cowburn RF, Winblad B & Pei JJ (2005) Mechanism of zinc-induced phosphorylation of p70 S6 kinase and glycogen synthase kinase 3beta in SH-SY5Y neuroblastoma cells. J Neurochem 92, 11041115.
  • 26
    Wang X, Li W, Williams M, Terada N, Alessi DR & Proud CG (2001) Regulation of elongation factor 2 kinase by p90RSK1 and p70 S6 kinase. EMBO J 20, 43704379.
  • 27
    Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, Oroz LG, Scaravilli F, Easton DF, Duden RB, O'Kane CJ & Rubinsztein DC (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 36, 585595.